Merrimack Pharmaceuticals Stock Price To Sales
Merrimack Pharmaceuticals fundamentals help investors to digest information that contributes to Merrimack Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Merrimack Stock. The fundamental analysis module provides a way to measure Merrimack Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Merrimack Pharmaceuticals stock.
Merrimack |
Merrimack Pharmaceuticals Company Price To Sales Analysis
Merrimack Pharmaceuticals' Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
CompetitionBased on the latest financial disclosure, Merrimack Pharmaceuticals has a Price To Sales of 0.0 times. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The price to sales for all United States stocks is 100.0% higher than that of the company.
Merrimack Price To Sales Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Merrimack Pharmaceuticals' direct or indirect competition against its Price To Sales to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Merrimack Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Merrimack Pharmaceuticals by comparing valuation metrics of similar companies.Merrimack Pharmaceuticals is currently under evaluation in price to sales category among its peers.
Merrimack Fundamentals
| Return On Equity | -0.0112 | |||
| Return On Asset | -0.0107 | |||
| Current Valuation | (20.36 M) | |||
| Shares Outstanding | 14.79 M | |||
| Shares Owned By Insiders | 1.19 % | |||
| Shares Owned By Institutions | 62.97 % | |||
| Number Of Shares Shorted | 842.49 K | |||
| Price To Earning | 65.70 X | |||
| Price To Book | 11.38 X | |||
| Gross Profit | (9.1 M) | |||
| EBITDA | (2.18 M) | |||
| Net Income | (1.18 M) | |||
| Cash And Equivalents | 13.36 M | |||
| Cash Per Share | 1.00 X | |||
| Debt To Equity | 33.90 % | |||
| Current Ratio | 31.85 X | |||
| Book Value Per Share | 15.25 X | |||
| Cash Flow From Operations | (1.52 M) | |||
| Short Ratio | 8.65 X | |||
| Earnings Per Share | (0.09) X | |||
| Price To Earnings To Growth | 0.07 X | |||
| Target Price | 4.0 | |||
| Beta | 1.42 | |||
| Market Capitalization | 223.75 M | |||
| Total Asset | 19.19 M | |||
| Retained Earnings | (548.82 M) | |||
| Working Capital | 18.74 M | |||
| Current Asset | 89.62 M | |||
| Current Liabilities | 88.28 M | |||
| Net Asset | 19.19 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Other Consideration for investing in Merrimack Stock
If you are still planning to invest in Merrimack Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Merrimack Pharmaceuticals' history and understand the potential risks before investing.
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Stocks Directory Find actively traded stocks across global markets | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules |